Why $ZYNE skyrocketed this week
Jazz Pharmaceuticals 
JAZZ agreed to buy GW Pharmaceuticals GGWPH for $7.2 billion last wednesday sending shares of fellow epilepsy-focused biotech companies ZZYNE flying.
"The acquisition allows Jazz to become a significant epilepsy player by adding Epidiolex, which exited 2020 with sales annualizing at about $576 million despite a challenging Covid environment and ahead of significant growth driven by a tuberous sclerosis label expansion and broad European launch,"
investors.com/news/technology/gwph-stock-rokets-jazz-pharma-takeover/?src=A00220
JAZZ agreed to buy GW Pharmaceuticals GGWPH for $7.2 billion last wednesday sending shares of fellow epilepsy-focused biotech companies ZZYNE flying."The acquisition allows Jazz to become a significant epilepsy player by adding Epidiolex, which exited 2020 with sales annualizing at about $576 million despite a challenging Covid environment and ahead of significant growth driven by a tuberous sclerosis label expansion and broad European launch,"
investors.com/news/technology/gwph-stock-rokets-jazz-pharma-takeover/?src=A00220
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.